Home / Press Release / Galderma S.A. invests CHF 150 million in two new factories in China

Galderma S.A. invests CHF 150 million in two new factories in China

Galderma S.A. a subsidiary of Nestle Skin Health has invested millions in Jiangsu province and Taizhou municipal government in China. These two state-of-the-art new factories are being developed to cater the skin care products and foods for special medical purposes (FSMP) of the consumers.

Nestle Skin Health is pioneering in providing extensive product portfolio with medically proven treatment for hairs, nails and skin care. Galderma SA is in collaboration with key opinion leaders throughout the globe to enhance its research and development segment of dermatological science. Nestle has a vision to fulfill the skin health requirements of consumers in China by continuous investment and sustainable growth strategies.

The statistics obtained from clinical studies conducted in mainland China, the prevalence rate of acne in teenagers were 39.2%. The prevalence rate was higher in males when compared to females. Further metaanalyses confirmed higher occurrence of acne in Southern China in comparison to Northern China. The two factories will cater the skin products to these regions respectively, to overcome facial pigmentation disorders and to provide skin nourishment.

Galderma SA has an extensive product portfolio of Epiduo®, Epiduo® Forte, and Differin (combination of adapelene and benzoyl peroxide), which are effective in the treatment of facial acne. Products such as Metvix® and Restylane Skinboosters provide optimum skin nutrition, rejuvenation, hydration and glowing skin radiance.

Analyst View:

Rising prevalence of skin pigmentation disorders, growing public health awareness and tough competition faced by dermal care product manufacturers in developing countries such as China, Taiwan, South Korea and South East Asia promote the demand for skin pigmentation disorder treatment products. Topical drugs such as adapelene, benzoyl peroxide, L-ascorbic acid, hydroquinone and azelaic acid are prescribed by dermatologist due to better clinical outcomes and minimal adverse effects.

Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on Rss
Add us on Google +